It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out that it's not an easy sell, especially to Wall Street.

It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out it's not an easy sell, especially to Wall Street.

Deal-making between universities and medical device companies has historically been limited. Not only are such deals often too pricey for device companies, the nature of medical device innovation--more likely to be incremental improvements than quantum leaps forward--gives physicians and entrepreneurs an edge over universities. But that may be changing, as this look at university/medical device deals in the first half of 1997 shows.